ArticleJournal of biological methods2025
Advantages of MabSelect VH3, a novel VH3-specific Protein A resin, over its two conventional counterparts in purifying a VHH-based trispecific antibody.
Article in Journal of biological methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Host cell protein impurities in therapeutic proteins: overview of advances in detection, nonconventional removal technologies and immunogenicity assessment.Journal of biological engineering · 2026Review
- Addressing challenging impurities in fusion proteins: A comprehensive review and cost-effective strategy for HCP and low molecular weight species control.Biotechnology progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Protein A affinity chromatography represents the most extensively used technique for initial product capture in antibody purification. The ligands of commercial Protein A resins from different, or even the same, vendors may exhibit distinct binding specificity. For example, MabSelect SuRe LX and MabSelect PrismA bind the antibody's fragment crystallizable region and both the fragment crystallizable and variable heavy chain 3 (VH3) regions, respectively, while MabSelect VH3, a newly launched Protein A resin, binds the VH3 region exclusively. Objective: This study aimed to compare the capabilities of three Protein A resins-namely, MabSelect SuRe LX, MabSelect PrismA, and MabSelect VH3-in removing byproducts associated with a variable domain of heavy chain-only antibody-based trispecific antibody (TsAb). Methods: Clarified culture harvest containing the TsAb was processed separately using MabSelect SuRe LX, MabSelect PrismA, and MabSelect VH3 columns. For each column, byproduct separation was monitored by analyzing relevant elution fractions with sodium dodecyl sulfate-polyacrylamide gel electrophoresis and size-exclusion chromatography-high-performance liquid chromatography. Results: MabSelect VH3 demonstrated superior byproduct removal performance compared with the other two Protein A resins. Conclusion: MabSelect VH3 is particularly suitable for the purification of bispecific antibodies and TsAbs, where the product and byproducts contain different numbers of VH3 domains. For multispecific antibody purification, screening different affinity resins with distinct binding specificity is recommended, as this can help identify the most effective option for separation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.